File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo

TitleAn Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo
Authors
KeywordsIVT mRNA
mRNA vaccine
electroporation
protamine
LNPs
Issue Date2021
PublisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/vaccines/
Citation
Vaccines , 2021, v. 9 n. 3, p. article no. 244 How to Cite?
AbstractThe mRNA-based vaccine approach is a promising alternative to traditional vaccines due to its ability for prompt development, high potency, and potential for secure administration and low-cost production. Nonetheless, the application has still been limited by the instability as well as the ineffective delivery of mRNA in vivo. Current technological improvements have now mostly overcome these concerns, and manifold mRNA vaccine plans against various forms of malignancies and infectious ailments have reported inspiring outcomes in both humans and animal models. This article summarizes recent mRNA-based vaccine developments, advances of in vivo mRNA deliveries, reflects challenges and safety concerns, and future perspectives, in developing the mRNA vaccine platform for extensive therapeutic use.
Persistent Identifierhttp://hdl.handle.net/10722/299347
ISSN
2023 Impact Factor: 5.2
2023 SCImago Journal Rankings: 1.201
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorRahman, MM-
dc.contributor.authorZhou, N-
dc.contributor.authorHuang, J-
dc.date.accessioned2021-05-10T07:00:30Z-
dc.date.available2021-05-10T07:00:30Z-
dc.date.issued2021-
dc.identifier.citationVaccines , 2021, v. 9 n. 3, p. article no. 244-
dc.identifier.issn2076-393X-
dc.identifier.urihttp://hdl.handle.net/10722/299347-
dc.description.abstractThe mRNA-based vaccine approach is a promising alternative to traditional vaccines due to its ability for prompt development, high potency, and potential for secure administration and low-cost production. Nonetheless, the application has still been limited by the instability as well as the ineffective delivery of mRNA in vivo. Current technological improvements have now mostly overcome these concerns, and manifold mRNA vaccine plans against various forms of malignancies and infectious ailments have reported inspiring outcomes in both humans and animal models. This article summarizes recent mRNA-based vaccine developments, advances of in vivo mRNA deliveries, reflects challenges and safety concerns, and future perspectives, in developing the mRNA vaccine platform for extensive therapeutic use.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/vaccines/-
dc.relation.ispartofVaccines-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectIVT mRNA-
dc.subjectmRNA vaccine-
dc.subjectelectroporation-
dc.subjectprotamine-
dc.subjectLNPs-
dc.titleAn Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo-
dc.typeArticle-
dc.identifier.emailHuang, J: jdhuang@hku.hk-
dc.identifier.authorityHuang, J=rp00451-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/vaccines9030244-
dc.identifier.pmid33799516-
dc.identifier.pmcidPMC8001631-
dc.identifier.scopuseid_2-s2.0-85102949094-
dc.identifier.hkuros322417-
dc.identifier.volume9-
dc.identifier.issue3-
dc.identifier.spagearticle no. 244-
dc.identifier.epagearticle no. 244-
dc.identifier.isiWOS:000634194700001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats